There is controversy over the extent to which fatty acids (FAs) derived from plasma free FAs (FFAs) 
T he transport of fatty acids (FAs) in plasma occurs in two ways: via (albumin-bound) free FAs (FFAs) and via triglycerides (TGs) that are transported in TG-rich lipoproteins. TGs in lipoproteins are hydrolyzed into FAs by the action of lipoprotein lipase (LPL), an enzyme expressed by tissues in need of the FA that is located at the capillary endothelium (1, 2) . The regulation of LPL is tissue-specific and dependent on the nutritional status, reflecting the FA requirements of the respective tissues at a specific time (1, (3) (4) (5) . For instance, postprandial LPL activity is high in white adipose tissue (WAT), whereas in the fasted state, LPL activity is high in muscle.
The mechanism(s) by which FA released by LPL activity enters the underlying tissues, and the interaction of this process with plasma FFA, is controversial. The literature appears to disagree regarding almost every aspect concerning the way FAs from both sources are transported into the underlying tissues. One issue is the role of proteins in the transport of FA over membranes (6 -8) .
Another issue is the relative contribution of plasma FFA and TG to cellular FA metabolism (9 -11) . One particularly confusing issue is the extent to which FA derived from plasma TG (TGFA) is recovered in plasma (11) (12) (13) . Views vary from complete and direct uptake of TGFA via some sort of channeling, to some but relatively little escape of TGFA to the circulation (11) , to complete mixing of labeled TGFA and FFA (13) . It has also been suggested that the amount of FA escaping immediate uptake is a highly regulated process (14, 15) and that impairment of this "extraction" or "entrapment" of TG-derived FA may be involved in the pathophysiology of insulin resistance and dyslipidemia.
The confusion may arise from methodological differences, different experimental models, nutritional status, and/or sources of TG-rich particles being employed. In this report, we have resolved some of the confusion by studying the fate of plasma FFA and TGFA in mice by employing different tracer methods, as described in the literature (11, 13) , and using different TG-rich substrates. Subsequently, we have studied the relative uptake of TGFA and FFA in liver, heart, and skeletal muscle, as well as in adipose tissue, because these organs have different LPL acitvities. In addition, we performed these experiments in the fed and fasted state because these conditions are known to specifically affect tissue LPL activity. We propose a model regarding the interactions between FFA and TGFA that incorporates and reconciles the data. Rensen et al. (16) and separated into three different fractions (average size 45, 80, and 150 nm) by ultracentrifugation. After preparation of the particles, the small (45-nm) particles were enriched with 1 mg purified recombinant apoE (17) per 50 mg TG by incubation at 37°C for 30 min. Preparation of infusion and bolus mixtures. [ 14 C]oleic acid was complexed to BSA as previously described (18) . [ 14 C]oleic acid was mixed with either lymph or lipid emulsions. Citrate was added to a final concentration of 3 g/ml. Infusion and bolus protocol. Mice were fasted overnight; all experiments were performed in anesthetized mice (0.5 ml/kg Hypnorm; Janssen Pharmaceutica, Beerse, Belgium and 12.5 mg/kg midazolam; Roche, Mijdrecht, the Netherlands) between 0800 and 1100 h. An infusion needle was placed in the tail vein, attached to a minipump (Harvard microdialysis low flow 11; Harvard Apparatus, Holliston, MA), and chylomicrons or lipid emulsions were infused at a rate of 0.2 ml/h for 1.5-2 h, after which steady state was achieved. A 150-l blood sample was taken by tail bleeding into paraoxon-coated capillaries to prevent ex vivo lipolysis (19) .
For the bolus injection protocol, a single 0.2-ml injection into the tail vein was applied and small 30-l blood samples were taken at regular time points after injection of the labeled mixture. At the last time point, a larger sample was taken for determination of TG and FA levels. Plasma analysis. TG, FA, and glucose were determined in plasma as previously described (20) . Lipids were extracted from plasma according to Bligh and Dyer (21 
where V in is the rate of label infusion (in Bq/min), q is the steady-state radioactivity of label in the total plasma pool (in Bq), and M is the poolsize (in mol), i.e., q/M represent the specific activity of the compound being traced. The fractional catabolic rate (FCR) is defined as the R d divided by the pool size:
Substituting R d using equation 1 gives:
The extent to which 
Dividing this rate with the infusion rate of [ 3 H]TG gives the extent to which label that was infused into the circulation as TG ends up in the circulation as FA. This ratio is defined as plasma TGFA recovery:
The plasma TGFA recovery, as calculated in this manner, does not discriminate between FAs being hydrolyzed without mixing with albumin-bound FA and FAs that are taken up as TG, i.e., by endocytosis of the whole particle. Therefore, we included labeled CE as a marker for whole-particle uptake when we used the lipid emulsion and followed the bolus experimental protocol (see below).
Compartmental modeling. The changes in time of TG-and FA-associated labels were fitted with a compartmental model ( Fig. 1 ), essentially as developed by Hultin et al. (13) . Where Hultin used two compartments for the FA label and a variable fraction in blood (or volume of distribution), we found better fits for both [ 3 H]FA and [ 14 C]FA when we used three compartments for FA. Thus, we explicitly modeled the rapid loss of label by redistribution and set the fraction in blood to 1. A single compartment with a variable volume of distribution sufficed to describe the TG kinetics accurately. The metabolic simulation software package Gepasi (23) was employed to estimate initial values for the kinetic parameters of the model. Gepasi has powerful algorithms to obtain absolute regression minima without the need for good estimates of the initial parameters (24) . WINSAAM (25) was subsequently used for fine-tuning by specifying errors in each time point.
The plasma TGFA recovery, as defined in equation 5, can be calculated from the compartmental modeling parameters as:
The contribution of TG-derived FA to the total FA flux was estimated as:
This equation assumes that 1 mol of TG releases 3 mol of FA. Theoretically, this should be considered as the upper boundary because formation of di-and monoacylglycerol are ignored. We cannot discriminate between label being taken up as acylglycerols or FA, but since the plasma TGFA recovery was high (see Table 1 The FCRs for TG and FA, calculated by the steady-state approach, also agreed well with those found with the compartmental modeling (Table 1) . After establishing that both tracer methods yielded the same results, we tested whether these results were specific for chylomicrons or whether they also apply to smaller TG-rich particles. Therefore, we used lipid emulsions and enriched these particles (average particle size 45 nm [16] ) with apoE, which is a good ligand to the VLDL receptor (26) . Because of the small size and presence of apoE, we expected that whole-particle uptake could lead to a quantitatively significant underestimation of the plasma recovery of TGFA (because TG-label not being lipolyzed but taken up as whole particle could not be distinguished from TG label being lipolyzed into FA and then being taken up without prior mixing with the plasma FA pool). Therefore, we included [ 3 H]-labeled CE as a marker for particle uptake and used the bolus injection protocol to follow the CE kinetics.
Again, TG-associated label was lost from plasma in a monoexponential manner, whereas FA kinetics needed at least two compartments (Fig. 3) . CE label decayed much slower than the TG label, indicating that in the first 15 min, lipolysis of TG dominated over whole-particle uptake. The initial volume of distribution was equal for both labels, which should be the case because they are part of the same particle. [ 3 H]FA label rapidly appeared in plasma and subsequently disappeared. In accordance with the chylomicron data, 89% of the label had to enter the plasma FA compartment to obtain a good fit. It was estimated that 11% of the total FA flux was originating from TG-derived FA (Table 1) .
To estimate the relative contribution of TG-lipolysis and plasma FFA to the total amount of FA taken up by tissues, we measured label retention after a 2-h infusion of Large differences in retention of label existed between tissues, and significant differences between the fasted and fed state were observed for liver, skeletal muscle, and WAT but not for heart muscle (Fig. 4) . 4C ) and lowest in liver (Fig. 4D) , irrespective of nutritional status. In adipose tissue, absolute [ 3 H] label in the TG store was twofold higher in the fed state (Fig. 4A) (Fig. 4B ) and relative to [ 14 C]FA retention (Fig. 4E) .
DISCUSSION
In the present study, we have studied the fate of FA derived from lipolysis of plasma TG. We observed that 80 -90% of infused TG tracer could be recovered as plasma FA, irrespective of tracer method or TG-rich particle used. individual rate constants of the FA kinetics, as they are very dependent on the model structure, whereas the overall kinetic constants, the FCR and R d , are related to the area under the curve of the tracer and are therefore robust to details of the model. It is the FCR of FA that determines the plasma TGFA recovery, not the individual rate constants, an argument also made by Hultin et al. (13) . Other studies have probed FA kinetics in mice in greater detail (27) .
The high recovery of TGFA in plasma is in agreement with the compartmental modeling studies in rats (13) . It does not agree, however, with the steady-state data presented by Wolfe et al. (11) . Their conclusion was that only 5% of the total FA flux originated from VLDL-derived FA. This implies that the plasma TGFA recovery in their system was very small. However, the authors used the specific activity of the infusate (i.e., of FA in the VLDLTG infusate) to calculate the flux from VLDL to FFA rather than the specific activity of plasma VLDLTG itself. In our view, the latter is the proper precursor enrichment to calculate rate of production of FFA from TG.
When Ͼ80% of FA generated by LPL is lost in plasma, one may raise doubts as to the usefulness of tissue-specific regulation of LPL activity. Yet, we have measured enormous differences in the ratio of [ 3 H]FA and [ 14 C]FA retention between tissues, which were also dependent on the fed or fasting state (Fig. 4) . Hultin et al. (13) C] ratios and the changes therein upon fasting reflect well-documented differences in LPL activity in these tissues (3, 5) . Thus, liver does not have LPL activity, and its relative retention of [ 3 H]TG is low (Fig. 4) . The uptake of [ 3 H] label in liver most probably reflects uptake of particle remnants that occurs primarily in liver. Skeletal muscle LPL, however, is upregulated during fasting and the relative amount of [ 3 H]TG label measured was indeed higher in the fasted state (Fig. 4E) . In WAT, the uptake of [ 3 H]TG was expected to be higher in the fed state because LPL is insulin stimulated in WAT (5, 28) . This is also reflected in the total amount of [ 3 H] counts (Fig. 4A ) but not in the ratio of [ 3 H] to [ 14 C] label retention (Fig. 4E ). In WAT, FA kinetics are complicated by the fact that in the fasted state, there is substantial intracellular FA hydrolysis of TG stores. It is clear from these data, however, that there is differential uptake of TGFA and FFA, which clearly follows the activity of LPL in these tissues. It is also important to note that in extrahepatic tissues, TGFA is (at least) equally important as plasma FFA, a conclusion that is in line with previous work (11, 29) .
The combination of near complete recovery of TGFA label in plasma and yet considerable differential uptake of these labels in the different tissues appears paradoxical. The paradox can be solved from the perspective that the labels actually enter the system at different sites. The simplest model that can solve the paradox is the capillary model (22) . This model consists of three compartments: an arterial compartment (A), a venous compartment (V), and a compartment representing the capillary bed (C) (Fig. 5) . In this model, we assume complete mixing of labels in compartment C, i.e., those (labeled) FA molecules that are released by LPL activity enter the same compartment, 
where q/M is the specific activity of tracer (see RESEARCH DESIGN AND METHODS), V in the tracer infusion rate, and R d is the rate of disappearance into tissues, in this system k 0C M C . This is the classical solution to estimate R d from specific activities of infusion experiments (i.e., equation 1). For [ 3 H]TGFA tracer, however, "injection" is at the capillary bed, where LPL is located, and the steady-state solution of such a system is different:
Here, V LPL rather than V in is used to stress the fact that the "infusion rate" is determined by the local LPL activity. It follows that the capillary specific activity (q C /M C ) differs from the one at the sampling site (q A /M A ) with a factor that depends on the relative amount of label escaping immediate uptake. It should be noted that this ratio corresponds to the plasma TGFA recovery defined in equation 5. It is also related to the FA entrapment, as defined by Evans et al. (15) . In a system with multiple organs, the differences between q c /M c and q A /M A become even larger because the local "infusion rates" V LPL are determined by local LPL activity and may therefore differ greatly from the overall systemic "infusion rate" that determines the arterial specific activity. This model can therefore explain how a steady-state infusion model with complete local mixing of [ 14 C] and [ 3 H] label can give rise to differential uptake of labels according to LPL activity. Figure 6 illustrates a proposal of the physiology underneath the behavior of the tracers. The activity of LPL is proposed to increase the local pool of FA close to the endothelium (Fig. 6) . The relative sensitivity of the uptake rate toward this increase in local FA therefore decides how much of the newly formed FA will be extracted and metabolized and how much will end up in venous plasma. Thus, tissue-specific regulation of LPL would allow for the production of a local increase in FA that then drives the (facilitated) diffusion of FA into the underlying cells.
This mechanism has implications for the current methods in experimental animals to measure tissue-specific uptake of FA, i.e., by FA analogs (BMIPP, bromopalmitate, or palmitate only [30, 31] ). These methods do not take into account the tissue-specific contribution of LPL to the local FA pool that may affect the local rate of label transfer. The proposed mechanism may have further implications for the interpretation of traditional tracer studies of plasma FFA turnover and oxidation. The release of FAs from adipose tissue and plasma fatty oxidation has been studied intensively by primed continuous infusions of labeled palmitate. Our data indicate that the release of FAs by adipose tissue in these studies may have been overestimated by the extent to which TGFA have contributed to the plasma FFA pool. Accordingly, the data on plasma FA oxidation include the contribution of unlabeled plasma TG-derived FAs to the plasma FA pool. However, the quantitative impact of the present data on these parameters in humans is uncertain.
In conclusion, our data indicate that the distinction between TGFA and plasma FFA is artificial. Traditionally, plasma TG metabolism and FFA metabolism are being studied in separate research areas; TG metabolism is mainly being studied in the context of cardiovascular disease and FFA metabolism in the context of diabetes. We propose a model in which FAs released from LPL are locally in rapid exchange with plasma FFAs and serve the important purpose of maintaining a driving force for (facilitated) diffusion. This model therefore embraces the importance of LPL and combines it with that of other factors involved in FA metabolism, such as acylation stimulating protein (32) and FAT/CD36 (6, 30) . Understanding these interactions between lipoprotein metabolism and FFA metabolism is crucial for understanding complex metabolic diseases such as the insulin resistance syndrome.
